Biohaven (Biohaven) Quality Rank

View and export this data going back to 2022. Start your Free Trial

What is Biohaven Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Biohaven Quality Rank Related Terms

Thank you for viewing the detailed overview of Biohaven's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Biohaven (Biohaven) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Ltd (NYSE:BHVN) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

215 Church Street, New Haven, CT, USA, 06510

Website

https://www.biohavenpharma.com

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.

Executives

Irina Antonijevic	director	215 CHURCH STREET, NEW HAVEN CT 06510
John W Childs	director	111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Vlad Coric	director, officer: Chief Executive Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Matthew Buten	officer: Chief Financial Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Gregory Bailey	director	4 A CHESHAM STREET, LONDON X0 SW1X8DT
George C. Clark	officer: VP, Chief Accounting Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory	director	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Robert J Hugin	director	C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kimberly Gentile	officer: SVP, Clinical Operations	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Kishan Mehta	director	540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd.	10 percent owner	215 CHURCH STREET, NEW HAVEN CT 06510
Bruce Car	officer: Chief Scientific Officer	AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139